GRAIL has raised $3.22B across multiple funding rounds, including Series C, Series D, and post-IPO transactions. Headquartered in Menlo Park, California, United States, GRAIL develops the Galleri multi-cancer early detection blood test using ultra-deep sequencing of cell-free DNA and machine learning. Funding supported large clinical trials, sequencing technology scale-up, and regulatory engagement to advance population-scale cancer screening. The company is focused on detecting multiple cancers in blood earlier than traditional methods, enabling timely interventions and improved patient outcomes.
Keep reading to learn how GRAIL is shaping next-generation molecular diagnostics.
What Is GRAIL and What Does It Do?
GRAIL, founded in 2016 by Jeff Huber and Mostafa Ronaghi, is a molecular diagnostics company based in Menlo Park, California, United States.
GRAIL employs 491 people (as of 2020 data) and develops blood-based screening tests for early cancer detection using ultra-deep sequencing of cell-free DNA. The company runs large clinical validation programs and works with regulators and payers to bring multi-cancer detection to clinical practice.
How Much Funding Has GRAIL Raised?
1. Post IPO
- Amount Raised: $325M
- Date: Oct 20, 2025
- Lead Investors: Deep Track Capital, Farallon, Braidwell
- Purpose: Commercial scale, distribution, and further validation
2. Series D
- Amount Raised: $390M
- Date: Nov 27, 2019
- Lead Investors: PSP Investments, CPP Investments, Illumina
- Purpose: Expand trials, regulatory pathway, and commercialization prep
3. Series C
- Amount Raised: $300M
- Date: May 21, 2018
- Lead Investors: Ally Bridge Group, Hillhouse, Sequoia Capital China, others
- Purpose: Scale sequencing capacity and clinical studies
Total Funding Raised: $3.22B
Latest Funding Date: Oct 2025
Key Investors
- Illumina
- Details: Leading sequencing company and early strategic investor in GRAIL
- Focus Areas: Genomics, diagnostics, sequencing platforms
- Notable Investments / Partnerships: Illumina spun out and later acquired/partnered with GRAIL
- Arch Venture Partners
- Details: Early-stage life-science investor focused on scientific breakthroughs
- Focus Areas: Genomics, biotech, diagnostics
- Notable Investments: Illumina (early), Alnylam, Moderna, GRAIL, Juno Therapeutics
- PSP Investments / CPP Investments
- Details: Canadian pension investors with private-market allocations
- Focus Areas: Large growth rounds, biotech, infrastructure
- Notable Investments: Large-scale healthcare and biotech investments globally
- Deep Track Capital / Farallon
- Details: Long-horizon institutional investors backing public & private healthcare innovators
- Focus Areas: Late-stage biotech, diagnostics, life sciences
- Notable Investments: Various late-stage biotech and diagnostics platforms
- Hillhouse / Ally Bridge (China investors)
- Details: Asian growth investors supporting life sciences scale-ups
- Focus Areas: Biotech, diagnostics, healthcare commercialization
- Notable Investments: Healthcare platforms and emerging biotech companies
Where Is GRAIL’s Headquarters?
GRAIL is headquartered in Menlo Park, California, United States, within the Bay Area life-sciences cluster and near major sequencing and biotech partners.
What’s Next for GRAIL?
GRAIL will focus on scaling commercial rollout of the Galleri test, payer coverage and guideline inclusion, ongoing registry studies, and next-generation assays to broaden sensitivity and use cases.
Get Investor & Funding Insights with TexAu
TexAu helps sales and business teams uncover detailed fundraising information on companies like GRAIL. Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.
Sign up for Free to start uncovering detailed investor and funding insights.
